卵巢癌术前腹腔化疗的临床应用及其评价  

Clinical application of intraperitoneal chemotherapy before surgery for ovarian cancer and its evaluation

作　　者：史佃云[1] 肖梅[1] 陈赛英[1] 杨斌[1] 朱启江[1] 徐萍萍[1] 苏成芳[1] 

机构地区：[1]解放军八一医院妇产科,南京210002

出　　处：《临床肿瘤学杂志》2008年第11期1000-1004,共5页Chinese Clinical Oncology

摘　　要：目的:探讨术前腹腔化疗对卵巢癌的临床应用价值。方法:对60例Ⅱ～Ⅳ期卵巢癌患者术前实施CAP或TP方案腹腔化疗,肿瘤减灭手术后再行6个疗程治疗,观察腹水和血清肿瘤标记物CA-125及CA19-9的变化,记录并分析近期疗效、肿瘤复发及患者生存情况。结果:经1～3个疗程的腹腔化疗,CA-125及CA19-9显著下降,癌性腹水基本消退,肿瘤缩小并易与周围组织分离,使所有病例均获得满意的手术,促腹水消退治疗有效率高达98.3%,并使患者的疾病无进展生存期明显延长,毒副作用并不严重。结论:术前腹腔化疗对卵巢癌的临床治疗具有积极作用,能有效改善手术条件,减少扩散病灶残留,提高生存质量。Objective：To investigate the clinical efficacy of intraperitoneal chemotherapy before surgery for ovarian cancer. Methods：Sixty patients with stage Ⅱ-Ⅳ of ovarian cancer were treated with intraperitoneal chemotherapy of CAP or TP regimen followed by a surgery treatment and another chemotherapy for 6 cycles. And then the efficiency of the therapy was evaluated by analyzing the changes of ascites, the serum CA-125 and CA19-9 levels and the findings in the operation, and investigating the recurrence of cancer and the survival. Results：After 1-3 cycles of intraperitoneal chemotherapy, serum levels of CA-125 and CA19-9 and carcinous ascites significantly reduced in all patients, ascites reduce was over 50% in 98.3% cases ; all cases were successfully treated with cytoreduction and it was found during the operation that bulky tumor was reduced and looser so as to be easily isolated and removed; PFS of the patients was prolonged, while the toxicity and side-effects were not so serious as beyond the patient toleration. Conclusion：Intraperitoneal chemotherapy before surgery for ovarian cancer has an active efficacy in the clinic, being able to improve conditions of surgery and increase the opportunity of maximal cytoreduction, and prolong survival of the patients, and should be a good selection for the treatment of advanced ovarian cancer.

关 键 词：卵巢癌 腹腔化疗 临床应用 评价 

分 类 号：R737.31[医药卫生—肿瘤]